Clinical Trial Update: LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial of LXE408 for primary visceral leishmaniasis in Ethiopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• LXE408 (LXE408)

Snippet

Sponsor: Drugs for Neglected Diseases | Conditions: Primary Visceral Leishmaniasis | Phase 2 | Status: COMPLETED